- Home
- BRT vs CCCC Comparison
BRT vs CCCC Comparison
Compare BRT & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BRT | CCCC |
|---|---|---|
| Founded | 1972 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 284.9M | 240.3M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | BRT | CCCC |
|---|---|---|
| Price | $14.91 | $2.44 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $19.75 | $8.50 |
| AVG Volume (30 Days) | 96.2K | ★ 1.4M |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | ★ 6.64% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $98,001,000.00 | $30,108,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.72 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 1.30 | N/A |
| 52 Week Low | $14.00 | $1.09 |
| 52 Week High | $19.30 | $4.70 |
Technical Indicators
Market Signals| Indicator | BRT | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 54.76 | 46.45 |
| Support Level | $14.45 | $2.50 |
| Resistance Level | $15.15 | $2.69 |
| Average True Range (ATR) | 0.31 | 0.18 |
| MACD | 0.07 | -0.02 |
| Stochastic Oscillator | 76.00 | 7.93 |
Price Performance
Historical ComparisonAbout BRT BRT Apartments Corp. (MD)
BRT Apartments Corp is a real estate investment trust company. The company is focused on the ownership, operation, and development of multi-family properties. BRT also owns and operates other real estate assets. All of the Company's assets are comprised of multi-family real estate assets generally leased to tenants on a one-year basis.
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.